AIM2 and neoplasm: The mechanism of action for ICT-107 involves pulsing autologous dendritic cells with peptide epitopes from six antigens—MAGE-1, HER-2, AIM-2, TRP-2, gp100, and IL13Ra2—targeting both tumor cells and cancer stem cells to reduce tumor heterogeneity and limit tumor escape [42].